ASHLEY BOUKNIGHT: Open Payments
NPI 1205440351 · OKLAHOMA CITY, OK. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,713 in 129 payments from 16 companies in 2025. Trend: 2023 $1,619 · 2024 $1,895 · 2025 $2,713
Food & beverage: $2,419Consulting: $200Education: $94
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 57 | $1,137 |
| Janssen Biotech, Inc. | 15 | $256 |
| GENZYME CORPORATION | 8 | $234 |
| Madrigal Pharmaceuticals | 7 | $193 |
| Takeda Pharmaceuticals U.S.A., Inc. | 7 | $138 |
| Lilly USA, LLC | 5 | $134 |
| Gilead Sciences, Inc. | 6 | $99 |
| Aimmune Therapeutics, Inc. | 4 | $97 |
| Ipsen Biopharmaceuticals, Inc | 5 | $88 |
| Regeneron Healthcare Solutions, Inc. | 3 | $77 |
Products named: RINVOQ, DUPIXENT, TREMFYA, REZDIFFRA, CREON, SKYRIZI, OMVOH, LINZESS.
Industry payments across OK — which companies pay providers there.
